Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

BACKGROUND: The development of targeted therapies has undoubtedly broadened therapeutic options for patients with colorectal cancer (CRC). The use of bevacizumab to reduce angiogenesis has been associated with improved clinical outcomes. However, an urgent need for prognostic/predictive biomarkers f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Paiva, Tadeu Ferreira, de Jesus, Victor Hugo Fonseca, Marques, Raul Amorim, da Costa, Alexandre André Balieiro Anastácio, de Macedo, Mariana Petaccia, Peresi, Patricia Maria, Damascena, Aline, Rossi, Benedito Mauro, Begnami, Maria Dirlei, de Lima, Vladmir Cláudio Cordeiro
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4579833/
https://ncbi.nlm.nih.gov/pubmed/26394830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1648-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi